Global Transplantation and Alternatives Market 2022 - Snapshot
The global transplantation and alternatives market market is projected to rise by USD 54 billion by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 7.4 percent during the forecast period.
This industry report offers market estimates of the global market, followed by a detailed analysis of the product, and region. The global market data on transplantation and alternatives can be segmented by product: alternatives, immunosuppressants, solid organ preservation solutions, tissue products, tissue typing. The alternatives segment is estimated to account for the largest share of the global transplantation and alternatives market. Transplantation and alternatives market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). North America held the largest revenue share in 2021.
The alternatives market is further segmented into orthopedic alternatives, ventricular assist devices (VADs), others. The orthopedic alternatives segment held the largest share of the global transplantation and alternatives market in 2021 and is anticipated to hold its share during the forecast period. Furthermore, the immunosuppressants market has been categorized into anti-proliferative agents, calcineurin inhibitors, m-TOR inhibitors, polyclonal antibodies, T-cell costimulation blocker. In 2021, the calcineurin inhibitors segment made up the largest share of revenue generated by the transplantation and alternatives market. The tissue products market is further divided into heart valves, cornea, orthobiologics, peripheral blood stem cells, skin grafts, soft tissue, vascular grafts. Among these, the peripheral blood stem cells segment was accounted for the highest revenue generator in 2021.
The report also includes the profiles of leading companies such as Amgen Inc., Bayer AG, Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
This industry report offers market estimates of the global market, followed by a detailed analysis of the product, and region. The global market data on transplantation and alternatives can be segmented by product: alternatives, immunosuppressants, solid organ preservation solutions, tissue products, tissue typing. The alternatives segment is estimated to account for the largest share of the global transplantation and alternatives market. Transplantation and alternatives market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). North America held the largest revenue share in 2021.
The alternatives market is further segmented into orthopedic alternatives, ventricular assist devices (VADs), others. The orthopedic alternatives segment held the largest share of the global transplantation and alternatives market in 2021 and is anticipated to hold its share during the forecast period. Furthermore, the immunosuppressants market has been categorized into anti-proliferative agents, calcineurin inhibitors, m-TOR inhibitors, polyclonal antibodies, T-cell costimulation blocker. In 2021, the calcineurin inhibitors segment made up the largest share of revenue generated by the transplantation and alternatives market. The tissue products market is further divided into heart valves, cornea, orthobiologics, peripheral blood stem cells, skin grafts, soft tissue, vascular grafts. Among these, the peripheral blood stem cells segment was accounted for the highest revenue generator in 2021.
The report also includes the profiles of leading companies such as Amgen Inc., Bayer AG, Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
- Get a detailed picture of the Global Transplantation and Alternatives Market
- Identify segments/areas to invest in over the forecast period in the Global Transplantation and Alternatives Market
- Understand the competitive environment, the market’s leading players
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
PART 1. SUMMARY
PART 2. INTRODUCTION
Study period
Geographical scope
Market segmentation
PART 3. TRANSPLANTATION AND ALTERNATIVES MARKET OVERVIEW
PART 4. MARKET BREAKDOWN BY PRODUCT
Alternatives
Immunosuppressants
Solid organ preservation solutions
Tissue products
Tissue typing
PART 5. MARKET BREAKDOWN BY REGION
Asia Pacific
Europe
North America
Rest of the World (RoW)
PART 6. KEY COMPANIES
Amgen Inc.
Bayer AG
Bristol-Myers Squibb Company (BMS)
F. Hoffmann-La Roche AG
Novartis AG
Pfizer Inc.
PART 7. METHODOLOGY
PART 2. INTRODUCTION
Study period
Geographical scope
Market segmentation
PART 3. TRANSPLANTATION AND ALTERNATIVES MARKET OVERVIEW
PART 4. MARKET BREAKDOWN BY PRODUCT
Alternatives
Immunosuppressants
Solid organ preservation solutions
Tissue products
Tissue typing
PART 5. MARKET BREAKDOWN BY REGION
Asia Pacific
Europe
North America
Rest of the World (RoW)
PART 6. KEY COMPANIES
Amgen Inc.
Bayer AG
Bristol-Myers Squibb Company (BMS)
F. Hoffmann-La Roche AG
Novartis AG
Pfizer Inc.
PART 7. METHODOLOGY
